William Blair & Company
KYNB

William Blair & Company’s Kyntra Bio KYNB Stock Holding History

William Blair & Company’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,894
Closed -$1.93M – 1898
2021
Q2 		$1.93M Sell
2,894
-3
-0.1% -$1.73K 0.01% 715
2021
Q1 		$2.51M Buy
+2,897
New +$3.08M 0.01% 612
2016
Q4 		– Sell
-472
Closed -$244K – 1423
2016
Q3 		$244K Buy
472
+8
+2% +$3.77K ﹤0.01% 1088
2016
Q2 		$190K Buy
464
+70
+18% +$32.1K ﹤0.01% 1123
2016
Q1 		$209K Buy
394
+62
+19% +$30.9K ﹤0.01% 1054
2015
Q4 		$252K Sell
332
-108
-25% -$71.7K ﹤0.01% 1002
2015
Q3 		$241K Hold
440
– – ﹤0.01% 1215
2015
Q2 		$258K Sell
440
-2,537
-85% -$1.48M ﹤0.01% 1985
2015
Q1 		$2.33M Sell
2,977
-171
-5% -$133K ﹤0.01% 1267
2014
Q4 		$2.15M Buy
+3,148
New +$2.03M ﹤0.01% 1260

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

William Blair & Company's KYNB Position: Q3 2021 in Review

William Blair & Company sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 2,894 shares — an estimated $1.93M sold.

William Blair & Company first reported a position in KYNB in Q4 2014 and held it in 10 quarters. The position peaked at $2.51M in Q1 2021. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

  • William Blair & Company reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
  • William Blair & Company sold 2,894 Kyntra Bio shares in Q3 2021, an estimated $1.93M.
  • William Blair & Company first reported a position in Kyntra Bio in Q4 2014 and held it in 10 quarters.
  • William Blair & Company's Kyntra Bio position peaked at $2.51M in Q1 2021.
  • 164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on William Blair & Company's 13F filing for Q3 2021, filed 12 Nov 2021.